<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ltr Pharma Limited — News on 6ix</title>
<link>https://6ix.com/company/ltr-pharma-fpo</link>
<description>Latest news and press releases for Ltr Pharma Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 04 May 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ltr-pharma-fpo" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836674178dffbe2df15e430.webp</url>
<title>Ltr Pharma Limited</title>
<link>https://6ix.com/company/ltr-pharma-fpo</link>
</image>
<item>
<title>SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/spontanr-phase-ii-interim-data-demonstrates-rapid-onset-and-pharmacokinetic-profile-addressing-fda-pre-ind-requirements-across-adult-and-65-populations</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/spontanr-phase-ii-interim-data-demonstrates-rapid-onset-and-pharmacokinetic-profile-addressing-fda-pre-ind-requirements-across-adult-and-65-populations</guid>
<pubDate>Mon, 04 May 2026 06:00:00 GMT</pubDate>
<description>LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") reports interim Phase II pharmacokinetic (PK) and safety data for SPONTAN®, demonstrating a rapid time to peak concentration (median Tmax 10 minutes) and a consistent safety profile, with no serious or severe treatment-emergent adverse events observed. The data support the Company's planned FDA 505(b)(2) regulatory pathway, subject to completion of final statistical analysis.</description>
</item>
<item>
<title>SPONTAN Phase II data show rapid onset, support FDA pathway</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/spontan-phase-ii-data-show-rapid-onset-support-fda-pathway</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/spontan-phase-ii-data-show-rapid-onset-support-fda-pathway</guid>
<pubDate>Fri, 01 May 2026 03:39:15 GMT</pubDate>
<description>SPONTAN Phase II data show rapid onset, support FDA pathway</description>
</item>
<item>
<title>SPONTAN Phase II Clinical Study Completes Recruitment</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/spontan-phase-ii-clinical-study-completes-recruitment</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/spontan-phase-ii-clinical-study-completes-recruitment</guid>
<pubDate>Thu, 05 Mar 2026 02:52:04 GMT</pubDate>
<description>SPONTAN Phase II Clinical Study Completes Recruitment</description>
</item>
<item>
<title>Appendix 4D and Half Yearly Report</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/appendix-4d-and-half-yearly-report-9</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/appendix-4d-and-half-yearly-report-9</guid>
<pubDate>Thu, 26 Feb 2026 02:33:38 GMT</pubDate>
<description>Appendix 4D and Half Yearly Report</description>
</item>
<item>
<title>SPONTAN Shows Positive Outcomes in Younger Men with ED</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/spontan-shows-positive-outcomes-in-younger-men-with-ed</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/spontan-shows-positive-outcomes-in-younger-men-with-ed</guid>
<pubDate>Mon, 02 Feb 2026 03:07:05 GMT</pubDate>
<description>SPONTAN Shows Positive Outcomes in Younger Men with ED</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/quarterly-activitiesappendix-4c-cash-flow-report-54</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/quarterly-activitiesappendix-4c-cash-flow-report-54</guid>
<pubDate>Wed, 28 Jan 2026 02:48:15 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>First Patients Dosed in SPONTAN Phase II Clinical Study</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/first-patients-dosed-in-spontan-phase-ii-clinical-study</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/first-patients-dosed-in-spontan-phase-ii-clinical-study</guid>
<pubDate>Thu, 22 Jan 2026 03:13:14 GMT</pubDate>
<description>First Patients Dosed in SPONTAN Phase II Clinical Study</description>
</item>
<item>
<title>TGA Provides Regulatory Clearance for SPONTAN Phase II</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/tga-provides-regulatory-clearance-for-spontan-phase-ii</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/tga-provides-regulatory-clearance-for-spontan-phase-ii</guid>
<pubDate>Wed, 10 Dec 2025 03:59:14 GMT</pubDate>
<description>TGA Provides Regulatory Clearance for SPONTAN Phase II</description>
</item>
<item>
<title>Ethics Approval Received for SPONTAN Phase II Clinical Study</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/ethics-approval-received-for-spontan-phase-ii-clinical-study</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/ethics-approval-received-for-spontan-phase-ii-clinical-study</guid>
<pubDate>Wed, 03 Dec 2025 03:40:11 GMT</pubDate>
<description>Ethics Approval Received for SPONTAN Phase II Clinical Study</description>
</item>
<item>
<title>LTR increases LevOmega stake to 43% with $1m investment</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/ltr-increases-levomega-stake-to-43percent-with-dollar1m-investment</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/ltr-increases-levomega-stake-to-43percent-with-dollar1m-investment</guid>
<pubDate>Mon, 06 Oct 2025 01:58:17 GMT</pubDate>
<description>LTR increases LevOmega stake to 43% with $1m investment</description>
</item>
<item>
<title>LTR Pharma secures 33% ownership in LevOmega Pty Ltd</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/ltr-pharma-secures-33percent-ownership-in-levomega-pty-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/ltr-pharma-secures-33percent-ownership-in-levomega-pty-ltd</guid>
<pubDate>Mon, 22 Sep 2025 02:48:27 GMT</pubDate>
<description>LTR Pharma secures 33% ownership in LevOmega Pty Ltd</description>
</item>
<item>
<title>FY25 Results Announcement</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/fy25-results-announcement-46</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/fy25-results-announcement-46</guid>
<pubDate>Fri, 29 Aug 2025 03:10:35 GMT</pubDate>
<description>FY25 Results Announcement</description>
</item>
<item>
<title>Appendix 4E and Annual Report to Shareholders</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/appendix-4e-and-annual-report-to-shareholders-8</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/appendix-4e-and-annual-report-to-shareholders-8</guid>
<pubDate>Fri, 29 Aug 2025 03:09:38 GMT</pubDate>
<description>Appendix 4E and Annual Report to Shareholders</description>
</item>
<item>
<title>SPONTAN Case Series - Strong Post-Prostatectomy Results</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/spontan-case-series-strong-post-prostatectomy-results</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/spontan-case-series-strong-post-prostatectomy-results</guid>
<pubDate>Mon, 25 Aug 2025 03:25:20 GMT</pubDate>
<description>SPONTAN Case Series - Strong Post-Prostatectomy Results</description>
</item>
<item>
<title>18-Month Shelf Life Strengthens SPONTAN Commercialisation</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/18-month-shelf-life-strengthens-spontan-commercialisation</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/18-month-shelf-life-strengthens-spontan-commercialisation</guid>
<pubDate>Fri, 22 Aug 2025 03:23:39 GMT</pubDate>
<description>18-Month Shelf Life Strengthens SPONTAN Commercialisation</description>
</item>
<item>
<title>SPONTAN 5x Faster Onset Validated in EU Journal</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/spontan-5x-faster-onset-validated-in-eu-journal</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/spontan-5x-faster-onset-validated-in-eu-journal</guid>
<pubDate>Wed, 20 Aug 2025 03:35:14 GMT</pubDate>
<description>SPONTAN 5x Faster Onset Validated in EU Journal</description>
</item>
<item>
<title>LTP Completes Extractables Study Milestone for SPONTAN</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/ltp-completes-extractables-study-milestone-for-spontan</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/ltp-completes-extractables-study-milestone-for-spontan</guid>
<pubDate>Mon, 30 Jun 2025 02:53:22 GMT</pubDate>
<description>LTP Completes Extractables Study Milestone for SPONTAN</description>
</item>
<item>
<title>Urological Expert Appointed to LTR Scientific Advisory Board</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/urological-expert-appointed-to-ltr-scientific-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/urological-expert-appointed-to-ltr-scientific-advisory-board</guid>
<pubDate>Wed, 21 May 2025 02:43:17 GMT</pubDate>
<description>Urological Expert Appointed to LTR Scientific Advisory Board</description>
</item>
<item>
<title>SPONTAN Expands Patient Access via National Pharmacy Network</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/spontan-expands-patient-access-via-national-pharmacy-network</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/spontan-expands-patient-access-via-national-pharmacy-network</guid>
<pubDate>Tue, 20 May 2025 02:48:18 GMT</pubDate>
<description>SPONTAN Expands Patient Access via National Pharmacy Network</description>
</item>
<item>
<title>LTR Signs Collaborative Agreement to Develop OMD Nasal Spray</title>
<link>https://6ix.com/company/ltr-pharma-fpo/news/ltr-signs-collaborative-agreement-to-develop-omd-nasal-spray</link>
<guid isPermaLink="true">https://6ix.com/company/ltr-pharma-fpo/news/ltr-signs-collaborative-agreement-to-develop-omd-nasal-spray</guid>
<pubDate>Thu, 08 May 2025 02:56:05 GMT</pubDate>
<description>LTR Signs Collaborative Agreement to Develop OMD Nasal Spray</description>
</item>
</channel>
</rss>